Harrow Health/$HROW
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Harrow Health
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
- Ticker
- $HROW
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 373
- Headquarters
- Nashville, United States
- Website
- www.harrow.com
Harrow Health Metrics
BasicAdvanced
$976M
-
-$1.00
0.24
-
Price and volume
Market cap
$976M
Beta
0.24
52-week high
$54.85
52-week low
$25.97
Average daily volume
600K
Financial strength
Current ratio
2.244
Quick ratio
1.995
Long term debt to equity
20.195
Total debt to equity
20.259
Interest coverage (TTM)
-0.12%
Profitability
EBITDA (TTM)
17.715
Gross margin (TTM)
73.28%
Net profit margin (TTM)
-13.51%
Operating margin (TTM)
-1.00%
Effective tax rate (TTM)
-11.36%
Revenue per employee (TTM)
$740,000
Management effectiveness
Return on assets (TTM)
-0.45%
Return on equity (TTM)
-116.07%
Valuation
Price to revenue (TTM)
3.509
Price to book
64.22
Price to tangible book (TTM)
-6.03
Price to free cash flow (TTM)
-71.184
Free cash flow yield (TTM)
-1.40%
Free cash flow per share (TTM)
-0.366
Growth
Revenue change (TTM)
21.05%
Earnings per share change (TTM)
250.14%
3-year revenue growth (CAGR)
38.95%
10-year revenue growth (CAGR)
33.37%
3-year earnings per share growth (CAGR)
21.34%
10-year earnings per share growth (CAGR)
-5.10%
What the Analysts think about Harrow Health
Analyst ratings (Buy, Hold, Sell) for Harrow Health stock.
Analyst projections of the future price of Harrow Health stock.
Bulls say / Bears say
VEVYE is gaining traction: Q2 revenue rose 58% year on year to $29.4 million, its branded dry-eye share nearly doubled to 14.6%, and expanded coverage with a top-three pharmacy benefit manager took effect in August. (Harrow, Inc.)
IHEEZO achieved record unit demand despite losing pass-through reimbursement, and its net price per unit rose about 25% from July; TRIESENCE demand also climbed 162% year on year. These trends point to stronger demand and improved pricing across key products. (Harrow, Inc.)
TYRVAYA adds a differentiated nasal treatment to Harrow’s dry-eye portfolio, complementing VEVYE. Harrow paid $30 million upfront and expects TYRVAYA to generate more than $30 million in 2027 revenue. (Harrow, Inc., Harrow, Inc.)
Harrow needs $235–250 million of second-half revenue to reach its $350–365 million full-year guidance, versus $114.9 million in the first half and $70.7 million in Q2. That requires a sharp acceleration in quarterly sales. (Harrow, Inc.)
Profitability and cash generation are weak: Q2 brought a $17.3 million net loss and negative adjusted EBITDA, while operating activities used $18.7 million in cash in the first half. Harrow also had $300 million of notes outstanding at an 8.625% coupon. (U.S. Securities and Exchange Commission)
Reported sales still show pressure beneath demand growth: IHEEZO revenue fell to $15.6 million from $18.3 million year on year despite record unit demand, while compounding revenue declined to $14.6 million from $21.5 million. The rebound in demand has not yet translated into consistent reported growth across the portfolio. (U.S. Securities and Exchange Commission, Harrow, Inc.)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
Harrow Health Financial Performance
Revenues and expenses
Harrow Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Harrow Health News
AllArticlesVideos
Funds containing Harrow Health
Fund name | Fund size | $HROW weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.07% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.07% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.